Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 148 Publications

25 Customer Reviews

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M1HMcmN6fG:2b4jpZ{BCe3OjeR?= NXLicYdoPTBizszN M36z[|Q5KGh? NIXFRlNFVVOR NXX5fYhJU2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? NITmNZkyODR7OU[0Ny=>
OVCA 429 NFLsOI5HfW6ldHnvckBCe3OjeR?= MVezNFAhdk1? MmSyOFghcA>? MoLvSG1UVw>? NIK2OpJFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> M3nFPVExQTl7N{[2
RPMI8226 NFvIW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNFAhdk1? M4TCOlQ5KGh? M4jGdGROW09? MV\JR|UxRTNyIH7N NYHHe|RLOTF|ME[0PFk>
Dox40 NEHsdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxNFAhdk1? MUO0PEBp NHXNPYRFVVOR MVXJR|UxRTRyIH7N NEn0Z2syOTNyNkS4PS=>
MR20 NXTmW2d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO5PFNtOTByIH7N MV20PEBp NVTuVWF2TE2VTx?= Mn\2TWM2OD1{MDDuUS=> NYLOd3ZpOTF|ME[0PFk>
LR5 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxNFAhdk1? MojMOFghcA>? MluzSG1UVw>? NH7XelhKSzVyPUKwJI5O M4GzN|EyOzB4NEi5
U266 M1zCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxNFAhdk1? NHnudm81QCCq NYXSVHJ{TE2VTx?= Ml[1TWM2OD1|IH7N MlLyNVE{ODZ2OEm=
IM-9 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXIXVIyODBibl2= NFXMRms1QCCq MVHEUXNQ M4nYSWlEPTB;NjDuUS=> M37FU|EyOzB4NEi5
Hs Sultan MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTtcFAyODBibl2= MoLkOFghcA>? M2Xve2ROW09? MmDBTWM2OD1{MDDuUS=> MlfYNVE{ODZ2OEm=
PAM-LY2 NULrU2V[TnWwY4Tpc44hSXO|YYm= MWmxNFAhdk1? MmDMNVIhcA>? MVPEUXNQ Ml64TY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= MlvXNVE{PTB7MUO=
PAM 212 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Ke|ExOCCwTR?= NULqSG5pPzJiaB?= M2HtT2ROW09? MYXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M{TSelEyOzVyOUGz
PAM-LY2 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLFZnkyODBibl2= NGf3WGc4OiCq MkPTSG1UVw>? NIrHR5hKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NF:3e4QyOTN3MEmxNy=>
B4B8 NF\mboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPwdI8yODBibl2= M3TyO|czKGh? M3XlSmROW09? M3HFfGlvcGmkaYTzJINmdGxidnnhZoltcXS7 M2LtZlEyOzVyOUGz
B7E3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Ln[VExOCCwTR?= MVy3NkBp NYDu[2ZRTE2VTx?= MWPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MYKxNVM2ODlzMx?=
UM-SCC-9 NWjqbohlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0XlExOCCwTR?= NXyxXnI4PzJiaB?= MUHEUXNQ M2DoN2lvcGmkaYTzJINmdGxidnnhZoltcXS7 NH3CNYUyOTN3MEmxNy=>
UM-SCC-11B NUL0SGpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO5dIkyODBibl2= NEWxfFQ4OiCq MX;EUXNQ NUfYeIhEUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= M4\DRlEyOzVyOUGz
H460 MmfUSpVv[3Srb36gRZN{[Xl? NYXYdG0yOTBizszN NXraU3dROjRiaB?= MWrEUXNQ M3\CS2lv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? M2GwTVEzPDl{MUG3
U266 NEXC[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TFW|UxOCCwZz;tcC=> MXi0PEBp MnHzSG1UVw>? Moe5TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MkfyNVI3OzF4MUm=
ARH77 M{P0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\adXRFPTByIH7nM41t NHrXSmI1QCCq M13oOGROW09? M3j4b2lvcGmkaYTzJINmdGxiZ4Lve5Rp NV3jPJB3OTJ4M{G2NVk>
WAD-1 NEPKZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS1NFAhdmdxbXy= NGLlWJc1QCCq NYHLdFB[TE2VTx?= M4PRN2lvcGmkaYTzJINmdGxiZ4Lve5Rp MnfRNVI3OzF4MUm=
U266/LR7 MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\jN4k2ODBibnevcYw> NWrJS4VxPDhiaB?= NEXKW5VFVVOR NF\sXW5KdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mo\ONVI3OzF4MUm=
U266/dox4 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrNXYpwPTByIH7nM41t MmnsOFghcA>? Mkj1SG1UVw>? NInZdJpKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NU\OV|V7OTJ4M{G2NVk>
RPMI8226/LR5 NGG1doNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe1NFAhdmdxbXy= NEPKNlM1QCCq NXjOXHZ4TE2VTx?= MYHJcohq[mm2czDj[YxtKGe{b4f0bC=> MoPhNVI3OzF4MUm=
H460 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTtNVAh|ryP Mn3xO|IhcA>? MmjaSG1UVw>? Mo\uTWM2OD1zMECgcm0> NF35WXMyOjZ|MU[yNC=>
H358 NEDVe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL3NVAh|ryP M17YfVczKGh? M3myWWROW09? NVjnUYs3UUN3ME23NEBvVQ>? MUexNlY{OTZ{MB?=
H322 M1fQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UNVAh|ryP M2jN[FczKGh? NYP3XlE1TE2VTx?= MXrJR|UxRTZ{MDDuUS=> MlfqNVI3OzF4MkC=
H460 MXPGeY5kfGmxbjDBd5NigQ>? NV[3d3JKOTByIH7N NHf6dWQzPCCq M3XuemROW09? MoH3TY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? NH7ZRXQyOjZ|MU[yNC=>
LNCap-Pro5 MnzySpVv[3Srb36gRZN{[Xl? NEnsVpEyKM7:TR?= M4LWW|QhcA>? M4riTmROW09? MXzTeIFjcWyrenXzJJA2Ow>? Mn:4NVQ3OTJ3M{K=
T29 MkCzRZBweHSxc3nzJGF{e2G7 NVrneWFKPTBibl2= M4fic|Q5KGhi MXzEUXNQ MULJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYfxcGljOTZ5N{ixO|k>
T29Kt1 MVLBdI9xfG:|aYOgRZN{[Xl? MWG1NEBvVQ>? NIXj[mk1QCCqIB?= MXnEUXNQ NELVWJNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MY[xOlc4QDF5OR?=
HCT116 M3\JOmFxd3C2b4Ppd{BCe3OjeR?= NVnBfY0xPTBibl2= MWW0PEBpKA>? M4nFTWROW09? MoLXTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHHRcYUyPjd5OEG3PS=>
HKe-3 M13sfWFxd3C2b4Ppd{BCe3OjeR?= NV74e|hGPTBibl2= M3XaT|Q5KGhi MoTmSG1UVw>? MUXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWCxOlc4QDF5OR?=
NB-1691 NILUcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexJO69VQ>? NU[wN3NCPzJiaB?= MXPJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? M3P2blE4Pjh7Nki0
CHLA-255 NWTXTmhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4myfVEh|ryP MV:3NkBp M{fDTGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?= NV3ucnZOOTd4OEm2PFQ>
SK-N-AS NYPQb|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjNU4E4OSEQvF2= NIDNRY04OiCq NYfQV4lVUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> M2C5OlE4Pjh7Nki0
NB-1691 MVPGeY5kfGmxbjDBd5NigQ>? NEfRWFYyOCCwTR?= MnHXNlQhcA>? NHexW4hUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm NXL6dZl5OTd4OEm2PFQ>
CHLA-255 M3XUZ2Z2dmO2aX;uJGF{e2G7 MXWxNEBvVQ>? NFPq[4ozPCCq MmfRUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? M13GdVE4Pjh7Nki0
RPMI 8226 NH34OllHfW6ldHnvckBCe3OjeR?= MnGxNlAhdk1? MoDWPEBp NF;Wc29UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MkfUNVk1OzZyNUC=
MM.1S NGX5ZYxHfW6ldHnvckBCe3OjeR?= NHzLNnUzOCCwTR?= MUO4JIg> NH:3ZXhUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MYixPVQ{PjB3MB?=
U266 M3\sfGZ2dmO2aX;uJGF{e2G7 NYLMSnVjOjBibl2= MYW4JIg> Ml;JV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NH;kUpcyQTR|NkC1NC=>
OPM1 NFf3dHVHfW6ldHnvckBCe3OjeR?= NU\Hcm1mOjBibl2= NXLROmtoQCCq MW\TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NEjVfogyQTR|NkC1NC=>
INA6 MkXHSpVv[3Srb36gRZN{[Xl? Ml22NlAhdk1? MoXZPEBp MVvTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NUHsSnF{OTl2M{[wOVA>
OPM2 MWTGeY5kfGmxbjDBd5NigQ>? MW[yNEBvVQ>? NUfaTW9tQCCq M1jnSHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MnPNNVk1OzZyNUC=
RPMI 8226 Ml;DSpVv[3Srb36gRZN{[Xl? NVzp[2RoOjBibl2= MkHTPEBp NYW1bGF2UW6mdXPld{BFVkFic4nueIhme2m| NXXjXJBDOTl2M{[wOVA>
BaF/3 NVi2OJJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MornNVAxKG6P MkGxOFghcA>? Mmj1TWM2OD14LkKgcm0> M4LtW|IxOzB3Nkmy
BaF/3-p210 NHzqepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S5OFExOCCwTR?= Mn\TOFghcA>? MnX5TWM2OD12Lkegcm0> MWOyNFMxPTZ7Mh?=
TCC-S MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXmxNFAhdk1? NI\XR4k1QCCq MkPyTWM2OD1{Lkigcm0> MUWyNFMxPTZ7Mh?=
BaF/3 NWXFV|hZTnWwY4Tpc44hSXO|YYm= M1XxUFYhdk1? MWW0PEBp MV;JcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= MlXSNlA{ODV4OUK=
BaF/3-p210 NVLMWJhDTnWwY4Tpc44hSXO|YYm= NH;hV4M3KG6P NWDzO4w{PDhiaB?= MmPhTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> NFLs[pMzODNyNU[5Ni=>
BaF/3-p210 NV;S[5puTnWwY4Tpc44hSXO|YYm= MofKOkBvVQ>? M2Trd|I1KGh? NV;PfFU4WmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= MYKyNFMxPTZ7Mh?=
Raji MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOxJO69VQ>? M{Dre|I1KGh? NFLvRnNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnThNlEyPzB7OEi=
LCL-1 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\HbXdROSEQvF2= NVXnfoU{OjRiaB?= MXvS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MoiwNlEyPzB7OEi=
LCL-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT0PGRMOSEQvF2= NXv1Rm9SOjRiaB?= MYTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M1r5PFIyOTdyOUi4
BJAB M2DTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV70W4g2OSEQvF2= M2WyUFI1KGh? MlS5VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NHzxOHozOTF5MEm4PC=>
SNT-13 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITyTJUyKM7:TR?= MWKyOEBp NETscpJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NYDQWZQxOjFzN{C5PFg>
SNT-16 NVfjbWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX6WYJvOSEQvF2= NHnpT4wzPCCq NX[2SoNUWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MnG0NlEyPzB7OEi=
Jurkat NXjJXGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGwemMyKM7:TR?= MmDWNlQhcA>? MoDwVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MnrzNlEyPzB7OEi=
KAI-3 MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKxJO69VQ>? M4\wdVI1KGh? M1;RRXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NWL3fVc5OjFzN{C5PFg>
SNK-6 M3joV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWixJO69VQ>? M2LmcVI1KGh? Mlu2VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NXuzW|lGOjFzN{C5PFg>
KHYG-1 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSxJO69VQ>? NXfuToJHOjRiaB?= M4q0WHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NU\HOVBJOjFzN{C5PFg>
SNT-16 MmDsRZBweHSxc3nzJGF{e2G7 NFHvNnIyKM7:TR?= M{KydVYhcA>? MXHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYD6ZnJUOjFzN{C5PFg>
Jurkat NGDsW4RCeG:ydH;zbZMhSXO|YYm= NYm4d3FJOSEQvF2= MUC2JIg> NEm3R29KdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYCybGhiOjFzN{C5PFg>
KAI-3 MVzBdI9xfG:|aYOgRZN{[Xl? MYKxJO69VQ>? MWW2JIg> MV;JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUOyNVE4ODl6OB?=
KHYG-1 NInZdHJCeG:ydH;zbZMhSXO|YYm= NY[wZpVWOSEQvF2= M1HCflYhcA>? NEC1R2VKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1SzTlIyOTdyOUi4
SNT-13 NVP6WFFuSW62aY\pdoFtKEG|c3H5 MljUNUDPxE1? M1vL[FI1KGh? NU\oR4JqUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M3Hsb|IyOTdyOUi4
SNT-16 NFzqSIFCdnSrdnnyZYwhSXO|YYm= M1PjXVEh|ryP M{D2O|I1KGh? MlzNTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX M{nSXlIyOTdyOUi4
KAI-3 NHnBO3JCdnSrdnnyZYwhSXO|YYm= MkS5NUDPxE1? NWfjN5RuOjRiaB?= MXvJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> Ml65NlEyPzB7OEi=
SNK-6 NHXDc3VCdnSrdnnyZYwhSXO|YYm= M2fGUFEh|ryP MUGyOEBp NV21cWs5UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY NH\aVpgzOTF5MEm4PC=>
RAW 264.7 M33PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmxNFAhdk1? M3vKSlQ5KGh? NYq2UXBsWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NUX3ZmJyOjJ2MkexOVQ>
A375 NU\KS5lRSXCxcITvd4l{KEG|c3H5 NVW5eWFYOTBibl2= MUCyOEBp MXHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NE\IcoszOzB5OUC4Ny=>
BLM NVL3Nm51SXCxcITvd4l{KEG|c3H5 NUO3PG5POTBibl2= NXu2[3hGOjRiaB?= NGnTWmFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MXeyN|A4QTB6Mx?=
A375 NUTENGpFSXW2b4DoZYd6KEG|c3H5 MUGxNEBvVQ>? Mn7oNVIhcA>? NGjKN5dKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MkftNlMxPzlyOEO=
BLM MoHuRZV1d3CqYXf5JGF{e2G7 MX6xNEBvVQ>? MlnvNVIhcA>? MnXnTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= NXnCS5lMOjNyN{mwPFM>
H1299 MYXBdI9xfG:|aYOgRZN{[Xl? NV\0cGFjQDBibl2= MWOyOEBp NInqTI1FVVOR NGLnO5dU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= M3LDTlI2OzJ|Nkmz
Hut-78 MULGeY5kfGmxbjDBd5NigQ>? MYKxNFAhdk1? MVmyOEBp MVTEUXNQ Mmm5SI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w NULx[GlIOjV4OEGzN|U>
H9 NGDQVJpHfW6ldHnvckBCe3OjeR?= NHywVG8yODBibl2= M{[2cVI1KGh? M1jYfmROW09? MlraSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w NX:wV2JPOjV4OEGzN|U>
HH Mn32SpVv[3Srb36gRZN{[Xl? NWH1dFRFOTByIH7N M1LCUlI1KGh? MYHEUXNQ M2H0ZYRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= M1\QflI2PjhzM{O1
Hut-78 NH7ZSIdOcWe{YYTpc44hSXO|YYm= MmLuNVAxKG6P MYCyOEBp MlvmSG1UVw>? NFnjR5VT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl NX7QU5FwOjV4OEGzN|U>
HH NE\WPWNOcWe{YYTpc44hSXO|YYm= NEewO4IyODBibl2= MnXhNlQhcA>? NUHMSGM4TE2VTx?= MUjS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFn M4D0PFI2PjhzM{O1
U937 NIDqU3lHfW6ldHnvckBCe3OjeR?= NVTEZoNROTByIH7N NUL6eXBuPiCq MorBTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? MVKyOVc6OTR5Nx?=
human PBMC NX\w[GY2TnWwY4Tpc44hSXO|YYm= NYeyW5kyOTByIH7N Mm\zNlQhcA>? NIDNdpFKdmS3Y3XzJGlNNThicnXs[YF{\Q>? M1zWSFI2PzlzNEe3
ES6 NHzLS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3mTWdKSzVyPUCuNFAzOSCwTR?= NIDFVoRUSU6JRWK=
SK-UT-1 NISzTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMU[zJI5O Ml[4V2FPT0WU
SH-4 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfQfVlKSzVyPUCuNVc{KG6P M3ru[nNCVkeHUh?=
TE-9 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMUiyJI5O NIjRNGdUSU6JRWK=
A253 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nZdmlEPTB;MD6yNFghdk1? NYrwTFRmW0GQR1XS
no-10 M1jje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH0[mFKSzVyPUCuNlEhdk1? M3vM[HNCVkeHUh?=
MMAC-SF NHXQNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrQTWM2OD1yLkKxOkBvVQ>? NVTDPWU3W0GQR1XS
A101D MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnGOJR1UUN3ME2wMlIzPSCwTR?= NFrM[YJUSU6JRWK=
NTERA-S-cl-D1 NH\abWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLwXm5xUUN3ME2wMlI1OyCwTR?= NWfJU3l1W0GQR1XS
8-MG-BA MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37RcmlEPTB;MD6yOUBvVQ>? MlT2V2FPT0WU
KNS-42 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\lR41RUUN3ME2wMlI2QCCwTR?= M3rvTXNCVkeHUh?=
LXF-289 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljHTWM2OD1yLkK2PUBvVQ>? MUTTRW5ITVJ?
OVCAR-4 M3vHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMki5JI5O Ml7oV2FPT0WU
LOUCY NGXFUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHiWVdKSzVyPUCuNlk{KG6P M4f0fnNCVkeHUh?=
BB65-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojxTWM2OD1yLkOwOEBvVQ>? M2PBcHNCVkeHUh?=
D-542MG M4fvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnscJVKSzVyPUCuN|I6KG6P MYTTRW5ITVJ?
ONS-76 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwM{Ogcm0> NVzBRYRDW0GQR1XS
BB30-HNC NXLPRow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwM{O1JI5O M1HpUHNCVkeHUh?=
KS-1 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwM{Sgcm0> MU\TRW5ITVJ?
A388 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XkOWlEPTB;MD6zOVYhdk1? NELRU3pUSU6JRWK=
ES8 MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\4TWM2OD1yLkSgcm0> NXTVfpJbW0GQR1XS
MZ2-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXj[Fc6UUN3ME2wMlQxPyCwTR?= NGLNeItUSU6JRWK=
HCC2998 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNEGyJI5O NFLpNJNUSU6JRWK=
D-247MG M3y4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\LfZhKSzVyPUCuOFE{KG6P NHu4RYxUSU6JRWK=
ACN NWPM[4V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwNEG3JI5O NGn4dZdUSU6JRWK=
LB2518-MEL MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnraTWM2OD1yLkSyOUBvVQ>? M1;CdXNCVkeHUh?=
ES1 NWXIfZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTUTWM2OD1yLkSzJI5O MmPmV2FPT0WU
HCE-T NILvWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LZ[WlEPTB;MD60N|khdk1? M4TsTnNCVkeHUh?=
OS-RC-2 NV;SfFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXZNJpKSzVyPUCuOFQhdk1? NV:wdZhYW0GQR1XS
MFH-ino NGWwNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvJWIpKSzVyPUCuOFQ{KG6P MofqV2FPT0WU
OCUB-M MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ZWmlEPTB;MD60OFchdk1? MmLUV2FPT0WU
CP66-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\PPXpKSzVyPUCuOFc{KG6P NITBc4NUSU6JRWK=
LB771-HNC NF\xSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXoO41KSzVyPUCuOFc1KG6P NH\1VFZUSU6JRWK=
DSH1 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWwS3hSUUN3ME2wMlQ5KG6P NXe0VZN6W0GQR1XS
HUTU-80 NUnmR|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPTNXN[UUN3ME2wMlU{OyCwTR?= M3H4fHNCVkeHUh?=
CESS NIXTTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNUO4JI5O MnrFV2FPT0WU
NCI-H747 M{\PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Dnd2lEPTB;MD61N|khdk1? MnjQV2FPT0WU
HT-144 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXyc2tPUUN3ME2wMlU4PiCwTR?= MXXTRW5ITVJ?
COLO-829 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjxT|k1UUN3ME2wMlYyPCCwTR?= NGO5bnNUSU6JRWK=
A4-Fuk NH[5TndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf5V3R1UUN3ME2wMlYzOyCwTR?= M324XXNCVkeHUh?=
GI-ME-N M4\SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNkO0JI5O MXPTRW5ITVJ?
LB831-BLC NXKzeZFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfaRmFsUUN3ME2wMlY1OSCwTR?= MUPTRW5ITVJ?
HOP-62 NXH5S|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tn[mlEPTB;MD62OFchdk1? NU\B[WZ[W0GQR1XS
BB49-HNC MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXye5JRUUN3ME2wMlY2OiCwTR?= MUjTRW5ITVJ?
D-336MG M3:xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnnSG9KSzVyPUCuOlU4KG6P NFHvcGFUSU6JRWK=
TK10 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfwTWM2OD1yLk[3PUBvVQ>? MoHuV2FPT0WU
Ramos-2G6-4C10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfyTWM2OD1yLk[5N{BvVQ>? M3y3OnNCVkeHUh?=
LB373-MEL-D MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zsVmlEPTB;MD63JI5O NIfobWRUSU6JRWK=
SF126 NF[1ZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwN{CxJI5O NHjNVJZUSU6JRWK=
UACC-257 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrkZ|lKSzVyPUCuO|Ehdk1? MnzRV2FPT0WU
KINGS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXFfppKSzVyPUCuO|IzKG6P M3;QXnNCVkeHUh?=
LS-513 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH1dYJKSzVyPUCuO|M6KG6P MnPtV2FPT0WU
GI-1 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPyT2tbUUN3ME2wMlc3PCCwTR?= NYrGT3Y{W0GQR1XS
ES7 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33udWlEPTB;MD63OlYhdk1? MXnTRW5ITVJ?
LB2241-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrsTWM2OD1yLkiwOEBvVQ>? MUHTRW5ITVJ?
D-263MG M3Xwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\kc2dzUUN3ME2wMlgxPyCwTR?= NGrEWI1USU6JRWK=
SW684 NVPzVlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKzTWM2OD1yLkiyNUBvVQ>? NVHMdFhCW0GQR1XS
ML-2 M4rPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf1WoZNUUN3ME2wMlgzOSCwTR?= NVrKXIk4W0GQR1XS
SK-LMS-1 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HrdWlEPTB;MD64OVQhdk1? NH72OZdUSU6JRWK=
TE-5 NGqw[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwOE[1JI5O MnnKV2FPT0WU
QIMR-WIL NX3xN5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPuTWM2OD1yLki4PUBvVQ>? MnjiV2FPT0WU
NCI-H1355 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITHbWVKSzVyPUCuPFk2KG6P MnTrV2FPT0WU
SNB75 M{DrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwOUGyJI5O NF;YT49USU6JRWK=
RXF393 M4\Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwOUG0JI5O MljVV2FPT0WU
IST-MEL1 NGDWXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDyXGZQUUN3ME2wMlkyPyCwTR?= MVHTRW5ITVJ?
SF268 NYLsOIlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXmOWxYUUN3ME2wMlkzOyCwTR?= M3;5VHNCVkeHUh?=
KALS-1 M{\qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Hle2lEPTB;MD65NlUhdk1? M33xeXNCVkeHUh?=
HC-1 NU\YRVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwOUe1JI5O MlixV2FPT0WU
SW872 NWfCWHp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\ueZRKSzVyPUCuPVk3KG6P NWq0U2llW0GQR1XS
PSN1 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwMEGgcm0> NEnWOoJUSU6JRWK=
TE-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmyVYFbUUN3ME2xMlA{KG6P NHHlUGZUSU6JRWK=
TE-10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwMEOgcm0> NVrmOpdFW0GQR1XS
RKO NEC2UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXOeXJKSzVyPUGuNFYhdk1? NVu4cHh1W0GQR1XS
LC-2-ad M1P2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LwRmlEPTB;MT6wPEBvVQ>? M{nzTXNCVkeHUh?=
SK-MM-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvYWm8xUUN3ME2xMlA6KG6P NIDyO2hUSU6JRWK=
VA-ES-BJ MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvhO2tKSzVyPUGuNFkhdk1? M4jYdHNCVkeHUh?=
MZ7-mel NWXtNXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KybmlEPTB;MT6wPUBvVQ>? NUnmcXAyW0GQR1XS
D-392MG Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMTDuUS=> MVPTRW5ITVJ?
CCRF-CEM NF34eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwMUOgcm0> NV\6RZgzW0GQR1XS
EM-2 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Bd2lEPTB;MT6xOkBvVQ>? NEn2VHZUSU6JRWK=
HAL-01 NH34RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\lRXpKSzVyPUGuNVghdk1? NH\WbohUSU6JRWK=
TE-8 M1;FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvae3BNUUN3ME2xMlE6KG6P MVnTRW5ITVJ?
NCI-H1882 NXzTcY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofkTWM2OD1zLkKgcm0> NFT4e2JUSU6JRWK=
Daudi NF\IcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH22[WxKSzVyPUGuNlIhdk1? NV3sbnhlW0GQR1XS
BL-41 M1z0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwMkWgcm0> NXPCNlFEW0GQR1XS
SR MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDlfHJKSzVyPUGuNlUhdk1? NU\CVo1JW0GQR1XS
KM12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfRT2FmUUN3ME2xMlI4KG6P MWXTRW5ITVJ?
K5 NFG2dIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELTbndKSzVyPUGuNlghdk1? MnexV2FPT0WU
A3-KAW M4O5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP2TWM2OD1zLkK4JI5O MYrTRW5ITVJ?
CMK Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37OfWlEPTB;MT6yPUBvVQ>? MYnTRW5ITVJ?
Calu-6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\4fVJKSzVyPUGuNlkhdk1? Ml3kV2FPT0WU
IST-SL2 M4S5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq4WGdKSzVyPUGuN|Ehdk1? NVG3O5RmW0GQR1XS
OPM-2 NITGPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;rWHR5UUN3ME2xMlM{KG6P M1\XW3NCVkeHUh?=
DU-4475 NW\zdZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW5cZJ4UUN3ME2xMlM3KG6P NV3WRZNRW0GQR1XS
ECC12 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwM{egcm0> NV32[lVtW0GQR1XS
L-540 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C3XmlEPTB;MT6zO{BvVQ>? MVrTRW5ITVJ?
CAS-1 NEjmdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwM{egcm0> NUnDfppWW0GQR1XS
PF-382 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPWTWM2OD1zLkS3JI5O MXLTRW5ITVJ?
LS-411N M1PDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkfGlEPTB;MT61N{BvVQ>? NESxWmRUSU6JRWK=
NCI-H69 M1fKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfvcI5KSzVyPUGuOVQhdk1? NGXPZVFUSU6JRWK=
NB12 M13VNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6U|NKSzVyPUGuOVYhdk1? M3T5OHNCVkeHUh?=
HEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITMNGpKSzVyPUGuOlEhdk1? M3PNcnNCVkeHUh?=
GCIY MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHsdlhDUUN3ME2xMlYzKG6P MUnTRW5ITVJ?
EHEB M1K2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwNkegcm0> M3TzOHNCVkeHUh?=
TGBC1TKB NILrZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe0bVlYUUN3ME2xMlcyKG6P NVnrWFZnW0GQR1XS
KURAMOCHI NHzJZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDJeFBKSzVyPUGuO|Ihdk1? NVTsS4Z5W0GQR1XS
U-266 NF7YXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjxTWM2OD1zLke2JI5O NYLISod1W0GQR1XS
LC4-1 NVzYdmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;KUlhQUUN3ME2xMlc6KG6P NFjyOXFUSU6JRWK=
NCI-H2126 NWnHZZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSxXYRlUUN3ME2xMlghdk1? NHvUTI5USU6JRWK=
NCI-H1092 M4f1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwODDuUS=> NH;2NohUSU6JRWK=
GB-1 M4\zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnzemtJUUN3ME2xMlgyKG6P MlTKV2FPT0WU
MV-4-11 M2mzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf1TGFnUUN3ME2xMlgzKG6P M3HJSXNCVkeHUh?=
Becker NIW5RYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jCUWlEPTB;MT64N{BvVQ>? Mn\DV2FPT0WU
MPP-89 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne3TWM2OD1zLki5JI5O NXfE[lZOW0GQR1XS
BE-13 M1;rO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPNVIdKSzVyPUGuPVMhdk1? MVrTRW5ITVJ?
697 M1TXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3YXmJYUUN3ME2xMlk6KG6P MormV2FPT0WU
NKM-1 NETFRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHvTWM2OD1{IH7N M1jMfnNCVkeHUh?=
NB13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\OSlJKSzVyPUKgcm0> M3e2XXNCVkeHUh?=
LS-123 M3LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJwMEKgcm0> M3XVZ3NCVkeHUh?=
NB17 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnGZZpvUUN3ME2yMlA1KG6P Ml3NV2FPT0WU
LAN-6 NHLvcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwMEWgcm0> MWDTRW5ITVJ?
EW-24 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJwMEigcm0> M33qU3NCVkeHUh?=
NOS-1 NV30eplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHVTWM2OD1{LkGxJI5O MVvTRW5ITVJ?
BL-70 NEXZWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPBU|lZUUN3ME2yMlEzKG6P MVrTRW5ITVJ?
GT3TKB MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLYT3NuUUN3ME2yMlEzKG6P NES1endUSU6JRWK=
HH M1nwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TyUmlEPTB;Mj6xN{BvVQ>? MWXTRW5ITVJ?
KE-37 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK4TlNFUUN3ME2yMlE{KG6P NU\lNXp6W0GQR1XS
MOLT-4 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPyU3pKSzVyPUKuNVMhdk1? NV3TN2gxW0GQR1XS
EKVX NWGySY84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\2ZW9iUUN3ME2yMlE1KG6P M{fWN3NCVkeHUh?=
KGN M4fJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzTWM2OD1{LkG1JI5O MlHMV2FPT0WU
ES4 NGHkS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwMU[gcm0> M1rCVHNCVkeHUh?=
SJSA-1 NXS0S5RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD1{LkKxJI5O M2DuT3NCVkeHUh?=
KMOE-2 NXrVWpYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwMkOgcm0> M3faOXNCVkeHUh?=
NB5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwMkegcm0> MU\TRW5ITVJ?
BC-1 NIHrZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfSTWM2OD1{LkOxJI5O MXzTRW5ITVJ?
NB10 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7DW2x5UUN3ME2yMlMzKG6P M1iyb3NCVkeHUh?=
RPMI-8226 NUfzNoNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFiwXHlKSzVyPUKuN|Uhdk1? MkHlV2FPT0WU
SCC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjPeIpLUUN3ME2yMlM4KG6P NGfLNWRUSU6JRWK=
ARH-77 NX6w[oZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq0OnVSUUN3ME2yMlM5KG6P M3O3WXNCVkeHUh?=
NCI-H748 NWm3fFQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJwM{mgcm0> MknzV2FPT0WU
KU812 NHT6dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPSeXRwUUN3ME2yMlQzKG6P NVPIWGh5W0GQR1XS
NCI-H64 NYTlVGlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXKR3Q2UUN3ME2yMlQ1KG6P NXz2N29qW0GQR1XS
NB69 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7L[Zo1UUN3ME2yMlQ3KG6P MnjEV2FPT0WU
KNS-81-FD NF60UY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX6TWM2OD1{LkS4JI5O MlzIV2FPT0WU
LB1047-RCC NXTINGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwNUegcm0> NETBdGNUSU6JRWK=
EB-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;qSo9KSzVyPUKuOlYhdk1? MWLTRW5ITVJ?
Mo-T NHvtZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe5W5dkUUN3ME2yMlc1KG6P NXLzXJpCW0GQR1XS
EW-16 NEfCdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLPbWU2UUN3ME2yMlc2KG6P NUXmOoxIW0GQR1XS
CTV-1 NEfJbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwODDuUS=> M1naPXNCVkeHUh?=
ETK-1 NUTBZ2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwOESgcm0> NUj2VnN1W0GQR1XS
C2BBe1 NFSzZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwOEmgcm0> MnWwV2FPT0WU
MOLT-16 NIew[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzzTWM2OD1{Lki5JI5O MVPTRW5ITVJ?
SW954 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PzWGlEPTB;Mj65JI5O MnPLV2FPT0WU
HT NELCTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn5RmhKSzVyPUOuNFIhdk1? NWjwT3R{W0GQR1XS
KARPAS-299 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fFZmlEPTB;Mz6wOkBvVQ>? MlvKV2FPT0WU
MONO-MAC-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwMTDuUS=> NWjXR41DW0GQR1XS
CGTH-W-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfyZ4szUUN3ME2zMlEhdk1? Mn3zV2FPT0WU
SK-PN-DW MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDwU|BwUUN3ME2zMlE1KG6P NEnnTpVUSU6JRWK=
CW-2 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPlTWM2OD1|LkKxJI5O MlLEV2FPT0WU
SK-N-DZ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwMk[gcm0> MVLTRW5ITVJ?
NEC8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDQXmFKSzVyPUOuN|Uhdk1? M3TO[HNCVkeHUh?=
LB996-RCC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCdlhKSzVyPUOuOEBvVQ>? M{LId3NCVkeHUh?=
DB M3XmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO3RpZiUUN3ME2zMlQyKG6P M2mxenNCVkeHUh?=
TE-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNwNEOgcm0> MYLTRW5ITVJ?
COR-L88 NFPvUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzVVXRuUUN3ME2zMlQ4KG6P M4G4enNCVkeHUh?=
LAMA-84 NX3nSZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPVeZhKUUN3ME2zMlQ6KG6P MoTrV2FPT0WU
MEG-01 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7pTWM2OD1|LkS5JI5O NFXGdHRUSU6JRWK=
LOXIMVI Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDSSpFuUUN3ME2zMlUhdk1? NIfXR45USU6JRWK=
RPMI-8402 M2DQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jCXWlEPTB;Mz61JI5O MXrTRW5ITVJ?
KARPAS-45 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PDV2lEPTB;Mz61OEBvVQ>? NFK4foNUSU6JRWK=
HCC1187 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTESWU4UUN3ME2zMlU1KG6P MmL3V2FPT0WU
MZ1-PC NXnDOpBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ZU3VKSzVyPUOuOVQhdk1? NUPyc5ZXW0GQR1XS
no-11 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNwNUWgcm0> NFW1e5pUSU6JRWK=
EVSA-T MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LMPWlEPTB;Mz62JI5O M4jlfnNCVkeHUh?=
DJM-1 M2HwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNwNkOgcm0> NHv6W4NUSU6JRWK=
COLO-684 NYHE[o13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PSZmlEPTB;Mz62OkBvVQ>? M4\sT3NCVkeHUh?=
NMC-G1 M1ju[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrMd29KSzVyPUOuOlghdk1? Mn;zV2FPT0WU
LC-1F Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TpUmlEPTB;Mz63OEBvVQ>? M1K5UnNCVkeHUh?=
RL95-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XjUWlEPTB;Mz63PUBvVQ>? MlrHV2FPT0WU
COLO-320-HSR MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILLemNKSzVyPUOuPVIhdk1? MXLTRW5ITVJ?
RCC10RGB MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD1|LkmzJI5O MVPTRW5ITVJ?
HD-MY-Z M2\aR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\QUWFKSzVyPUOuPVMhdk1? MmH0V2FPT0WU
NCI-H2141 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rjW2lEPTB;ND6wOUBvVQ>? M2nrTnNCVkeHUh?=
K-562 NVnENY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmTWM2OD12LkGyJI5O M1;l[XNCVkeHUh?=
NCI-H1648 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD0PWd{UUN3ME20MlE{KG6P NYrMeY5sW0GQR1XS
OMC-1 NI\ubVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HBO2lEPTB;ND6xPEBvVQ>? M{PU[nNCVkeHUh?=
LB647-SCLC M161U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXITWM2OD12LkKyJI5O MkLpV2FPT0WU
TE-12 M2jlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\a[mlEPTB;ND6yOUBvVQ>? MlO3V2FPT0WU
NOMO-1 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnwWYZKSzVyPUSuN|Mhdk1? MnexV2FPT0WU
Raji NX\tbGpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzjO4RyUUN3ME20MlQ3KG6P NUS1WHhNW0GQR1XS
NALM-6 M1LjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwNEmgcm0> MXTTRW5ITVJ?
HL-60 NW\TTJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6dYZKSzVyPUSuOlchdk1? NWnvUo8yW0GQR1XS
IST-SL1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwNkigcm0> NEG1[WlUSU6JRWK=
MHH-PREB-1 NXvMW4FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\2TWM2OD12Lki2JI5O NFHHWWFUSU6JRWK=
MHH-NB-11 NHnY[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fV[GlEPTB;ND65NUBvVQ>? M1fZcXNCVkeHUh?=
JiyoyeP-2003 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vaT2lEPTB;NTDuUS=> NVPJ[WxEW0GQR1XS
SBC-1 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO0S|gxUUN3ME21MlAyKG6P MmTLV2FPT0WU
CHP-126 NYTFcnlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnlZXJKSzVyPUWuNFYhdk1? NFfDcoVUSU6JRWK=
LU-139 M{Lse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[1TWM2OD13LkGzJI5O M321WHNCVkeHUh?=
NCI-SNU-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwMUegcm0> M{LXXHNCVkeHUh?=
SW962 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKxZoNKSzVyPUWuNlEhdk1? NHntcYZUSU6JRWK=
EW-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHRTWM2OD13LkOxJI5O MlzWV2FPT0WU
NCI-H1417 NY\sO4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTVwNUGgcm0> MVjTRW5ITVJ?
LU-65 M{O1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDtfZNjUUN3ME21Mlg1KG6P MnzqV2FPT0WU
D-502MG NGnkS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwM{egcm0> MknUV2FPT0WU
BC-3 NGLIbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TpU2lEPTB;Nj62NUBvVQ>? NWj3NnVjW0GQR1XS
GDM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIryWpNKSzVyPU[uO|chdk1? Mk\GV2FPT0WU
NCI-H2196 NHf5N|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHONWpKSzVyPU[uPEBvVQ>? NWHxcHBXW0GQR1XS
NB1 NGCxb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwOEigcm0> NH7QXYdUSU6JRWK=
NCI-H345 NVnxOpJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjlNGNWUUN3ME23MlIhdk1? Ml7aV2FPT0WU
SU-DHL-1 NEjobVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfkRoZ3UUN3ME23MlI1KG6P M2nafnNCVkeHUh?=
JVM-2 M{TFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTtO4JKSzVyPUeuNlghdk1? NW\BdYN5W0GQR1XS
LU-134-A NFSycnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLLNFZKSzVyPUeuN|khdk1? M1HGTHNCVkeHUh?=
NCI-H1694 M3O4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\PTWM2OD15LkW4JI5O MVXTRW5ITVJ?
NCI-SNU-16 NVPzR21lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC1UGZKSzVyPUeuOlUhdk1? NHjqNmxUSU6JRWK=
L-363 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ZTWM2OD15Lkegcm0> MnPWV2FPT0WU
KG-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTdwOUSgcm0> NVLLdmdbW0GQR1XS
MN-60 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTUO49OUUN3ME24MlE1KG6P NXX0VoVkW0GQR1XS
NB6 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknETWM2OD16LkS4JI5O NVzBWollW0GQR1XS
MLMA NUHt[4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnmT5pKSzVyPUiuPFUhdk1? MWLTRW5ITVJ?
ATN-1 NWDCVmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfLWI5KSzVyPUiuPFkhdk1? NGXYdolUSU6JRWK=
SK-NEP-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HCU2lEPTB;OT6wNUBvVQ>? NUj3fWZMW0GQR1XS
DMS-114 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\pd4cyUUN3ME25MlYzKG6P NV;Dc4NqW0GQR1XS
CTB-1 M3L1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LRU2lEPTB;OT62O{BvVQ>? NFzMb3VUSU6JRWK=
NCI-H2081 NUjJclcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi4WVdKSzVyPUGwMlA6KG6P NUjjRnNVW0GQR1XS
ES5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG4W3NKSzVyPUGwMlM5KG6P MYDTRW5ITVJ?
HCC1599 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFzLkmxJI5O M3TZeHNCVkeHUh?=
NCI-H23 NFeweFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\1bGpKSzVyPUGyMlEzKG6P MkL1V2FPT0WU
NCI-H1581 M1;Vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPyboVKSzVyPUGyMlI5KG6P NEjodI1USU6JRWK=
JVM-3 M1exbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXEU5VKSzVyPUGyMlk6KG6P M33YTHNCVkeHUh?=
NCI-SNU-1 MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLhTWM2OD1zMz6xPUBvVQ>? NVSxclZJW0GQR1XS
NB7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DMW2lEPTB;MUWuPVIhdk1? NIq3XGJUSU6JRWK=
JAR NVfB[mp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnvOGk4UUN3ME2xOk4yOyCwTR?= MYLTRW5ITVJ?
TGW NELu[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfTTWM2OD1zNj60PEBvVQ>? M2m4eXNCVkeHUh?=
U-87-MG M4rjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXuSWVlUUN3ME2xOk44PiCwTR?= M2mzZXNCVkeHUh?=
NCI-H1436 M4jx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPDU5A5UUN3ME2xO{4xOSCwTR?= MV3TRW5ITVJ?
GOTO NVS3W2FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDIUo9KUUN3ME2xO{4xPiCwTR?= MUnTRW5ITVJ?
COLO-800 NFHoNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\EPHNxUUN3ME2xO{43PCCwTR?= MWXTRW5ITVJ?
MFM-223 M{PRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\LTWM2OD1zNz65NUBvVQ>? NWHuOYFxW0GQR1XS
EW-18 NV7NRWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq0NpBKSzVyPUG3Mlk3KG6P NEfXXFBUSU6JRWK=
NB14 M4DPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXDVmxKSzVyPUG3Mlk5KG6P NHm0OmFUSU6JRWK=
EB2 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jYUWlEPTB;MUiuNFghdk1? NGrBNopUSU6JRWK=
EoL-1- Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3UTWM2OD1zOD6zNUBvVQ>? NEjIe4FUSU6JRWK=
NCCIT NEHiNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF6LkO2JI5O NWfhZopsW0GQR1XS
DG-75 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF6Lk[xJI5O NEDO[JdUSU6JRWK=
HCC2218 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17DdmlEPTB;MUmuOUBvVQ>? NWHTTpNHW0GQR1XS
TE-6 M1PRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJyLkC4JI5O M3;qdXNCVkeHUh?=
SF539 NEj2[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDSW5RsUUN3ME2yNE43PyCwTR?= MVXTRW5ITVJ?
NCI-H446 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\0SXY3UUN3ME2yNU4yQCCwTR?= NFnEfmZUSU6JRWK=
IST-MES1 NXjJV4M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ{Lke3JI5O NXftO|lMW0GQR1XS
NCI-H82 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TyNmlEPTB;MkOuNFIhdk1? MVLTRW5ITVJ?
HCC2157 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPuNmVKSzVyPUKzMlE{KG6P M2XKZ3NCVkeHUh?=
EW-12 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\pdldPUUN3ME2yN{4yPyCwTR?= M1uzO3NCVkeHUh?=
SIMA NVvHdXY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr1PHlKSzVyPUKzMlM5KG6P M33aSnNCVkeHUh?=
DOHH-2 NYDI[3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq2UIpKSzVyPUKzMlQ2KG6P NWrNUnJIW0GQR1XS
IM-9 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TYbmlEPTB;MkOuOVQhdk1? NVXjUmJCW0GQR1XS
EC-GI-10 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDETWM2OD1{ND6yN{BvVQ>? NYX1PGx7W0GQR1XS
HDLM-2 M1vCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ2LkW0JI5O M{[5N3NCVkeHUh?=
LS-1034 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrLWohYUUN3ME2yOU44PSCwTR?= MmDaV2FPT0WU
REH NVS0[Iw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxTZNtUUN3ME2yOk41OSCwTR?= NVPrbmJtW0GQR1XS
LU-165 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJ4LkeyJI5O NFXHV|dUSU6JRWK=
NH-12 M1TzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDBXVd{UUN3ME2yO{43PyCwTR?= M3XEdXNCVkeHUh?=
WSU-NHL NYq5fVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ6LkO5JI5O MWjTRW5ITVJ?
ECC4 NGfB[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJ6Lke5JI5O NXjnVmVwW0GQR1XS
OCI-AML2 NIfmZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ7Lk[5JI5O MW\TRW5ITVJ?
EW-3 NIT4So1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPwO2RKSzVyPUOwMlU6KG6P NIDGRVNUSU6JRWK=
NCI-H526 M4\FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN{LkW0JI5O NW\MdXlDW0GQR1XS
NCI-H719 NVS2V4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OyPGlEPTB;M{SuN|Ehdk1? NV2yRld{W0GQR1XS
KARPAS-422 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\pXFREUUN3ME2zOU4xPCCwTR?= NI\tbYNUSU6JRWK=
SK-MEL-1 NYrxdHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTN3LkG3JI5O MXjTRW5ITVJ?
ES3 NW\EbWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrBTWM2OD1|NT6xPUBvVQ>? MVXTRW5ITVJ?
UACC-812 NXfmUm1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TjOmlEPTB;M{WuOFQhdk1? NH;LXIRUSU6JRWK=
C8166 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy4do9KSzVyPUO1Mlchdk1? NF\OSFVUSU6JRWK=
MDA-MB-134-VI NGHyNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\QNWNHUUN3ME2zOU45PyCwTR?= M4LJbXNCVkeHUh?=
D-283MED MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K1UmlEPTB;M{euO|khdk1? NXHQWGkyW0GQR1XS
SHP-77 NYL0WGRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LVV2lEPTB;M{iuNFMhdk1? Mn\uV2FPT0WU
NCI-H2227 NX;lRm1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjzUHlKSzVyPUSwMlQ6KG6P NEXldotUSU6JRWK=
SKM-1 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWycpB2UUN3ME20Nk43OyCwTR?= MYTTRW5ITVJ?
L-428 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITrTJRKSzVyPUSzMlg3KG6P NY\Zb401W0GQR1XS
RPMI-6666 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTwTWM2OD12NT64PUBvVQ>? NF7UVVRUSU6JRWK=
NCI-H716 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjTVXh4UUN3ME20PE45OSCwTR?= NYqzTlZ1W0GQR1XS
DMS-79 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTVyLkexJI5O M4XnSnNCVkeHUh?=
RS4-11 NYnJb5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrtdYdlUUN3ME21NE45QCCwTR?= MkPhV2FPT0WU
NCI-H720 NFizRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTVzLkGxJI5O NFfZN2pUSU6JRWK=
MC-CAR M3rPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPvTWM2OD13MT61NkBvVQ>? MmLmV2FPT0WU
TALL-1 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfERWl[UUN3ME21N{46OSCwTR?= M2C3WHNCVkeHUh?=
NCI-N87 M3fnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTV2LkG4JI5O M1TSPHNCVkeHUh?=
P30-OHK NEjrTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1TWM2OD13ND62NUBvVQ>? MXXTRW5ITVJ?
LP-1 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS4UJBKSzVyPU[xMlI5KG6P NWW2W5kxW0GQR1XS
YT M4j1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:1b5BKSzVyPU[xMlghdk1? MnK1V2FPT0WU
MRK-nu-1 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zmTWlEPTB;NkGuPFIhdk1? M3q2ZnNCVkeHUh?=
BT-474 NWrUS2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnFbZA5UUN3ME22OUBvVQ>? NVPkS4czW0GQR1XS
NCI-H322M NXHWe2oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTrTWM2OD14Nj6xNUBvVQ>? MU\TRW5ITVJ?
NCI-H128 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTd2Lke3JI5O M{HVRnNCVkeHUh?=
KMS-12-PE MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTd4LkK0JI5O M1nnN3NCVkeHUh?=
KP-N-YS Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu4TWM2OD15Nj63OEBvVQ>? NXvLWYtyW0GQR1XS
ALL-PO M4OzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjUOYlKSzVyPUe3MlY3KG6P NF75[mNUSU6JRWK=
EW-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTd5Lke2JI5O NI\LVoVUSU6JRWK=
EW-11 NH;jc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTd6LkWyJI5O M{C1OnNCVkeHUh?=
SK-N-FI M1XxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\PcW5KSzVyPUiwMlIhdk1? M1rIZnNCVkeHUh?=
CAL-148 NWfkcVRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPrTWM2OD16MT64OEBvVQ>? MmXHV2FPT0WU
RL NUDBSm1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD16Nj6wPUBvVQ>? NWfaSo5tW0GQR1XS
AM-38 NYT2XHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXWcItKSzVyPUi4MlA5KG6P NF3QR|BUSU6JRWK=
RH-1 NVrQdWdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK4TWM2OD17OT64OUBvVQ>? MoPVV2FPT0WU
NCI-H1770 NHLMZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLqTWM2OD1zMEKuOFkhdk1? Mlu2V2FPT0WU
SIG-M5 M4PUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Gb5BKSzVyPUGwOU4xPiCwTR?= MmS0V2FPT0WU
GR-ST M{[1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXyTWM2OD1zMUOuN|Qhdk1? NEjLZWlUSU6JRWK=
ST486 NYXwTHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnTPYR5UUN3ME2xNVQvODZibl2= NGHZOGFUSU6JRWK=
NCI-H1650 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3UTWM2OD1zMUWuNlkhdk1? MoTsV2FPT0WU
MHH-CALL-2 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;MTWM2OD1zMUWuO{BvVQ>? NHjUflZUSU6JRWK=
BV-173 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF{Mj63NUBvVQ>? NYrsNFNwW0GQR1XS
MC116 NFHUOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnMeVBKSzVyPUG0PE45PSCwTR?= Mmm1V2FPT0WU
NCI-H524 M3[1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrpOGJKSzVyPUG1PU4yKG6P NX7jPGNmW0GQR1XS
SCLC-21H NFPMNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\OOmpNUUN3ME2xOVkvPDFibl2= NVjqTJlwW0GQR1XS
NCI-H1304 MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Wco1KSzVyPUG2PU4zOSCwTR?= MlfqV2FPT0WU
NCI-H510A NVLwdYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPWTWM2OD1zOEWuN|chdk1? MV\TRW5ITVJ?
NCI-H209 M3r5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHUUlFSUUN3ME2xPVYvPTJibl2= M4fqZ3NCVkeHUh?=
KM-H2 NVXYdFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG4TWM2OD1zOUeuNFUhdk1? NU[4OVkxW0GQR1XS
NCI-H1395 NWC0V4gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJzMD6xN{BvVQ>? NIHlV4JUSU6JRWK=
NCI-H1155 NX3sWVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\rTWM2OD1{M{CuN|Ihdk1? NYm1OXlTW0GQR1XS
COR-L279 NFzaWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HCSmlEPTB;MkWyMlE4KG6P MVjTRW5ITVJ?
NCI-H1299 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHYU4lKSzVyPUK2NU44OSCwTR?= NFnudodUSU6JRWK=
EW-22 M{jBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0emduUUN3ME2yOlMvPzVibl2= MU\TRW5ITVJ?
SK-MEL-2 M2rKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ6MT65JI5O NHjUWJZUSU6JRWK=
KASUMI-1 NGn0XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV35e4t{UUN3ME2yPFMvODVibl2= NVzxNGw2W0GQR1XS
NCI-H187 NYD6c4RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PQWmlEPTB;Mki3MlA5KG6P MX;TRW5ITVJ?
NCI-H2171 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljaTWM2OD1{OEiuPVIhdk1? Ml3lV2FPT0WU
LNCaP-Clone-FGC MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jvO2lEPTB;Mkm1MlI3KG6P NUXa[FM1W0GQR1XS
NCI-H1522 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof1TWM2OD1|MEeuNFUhdk1? M4jXRnNCVkeHUh?=
SCH NFT0fZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDuV5FKSzVyPUOyNk4zOiCwTR?= MmDzV2FPT0WU
THP-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC3PYpVUUN3ME2zNlIvPiCwTR?= NX3RXGxSW0GQR1XS
SNU-C1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H2V2lEPTB;M{[yMlA6KG6P M1PU[XNCVkeHUh?=
CA46 NEj5XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm1dWlKSzVyPUO3N{43OyCwTR?= MUXTRW5ITVJ?
NCI-H1963 M4LkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjzOpRKSzVyPUO4Ok4yQSCwTR?= NH\CT|VUSU6JRWK=
DEL MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN7MT6yO{BvVQ>? M4fMWXNCVkeHUh?=
TUR Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Me4c6UUN3ME2zPVYvPjFibl2= NFPOOmdUSU6JRWK=
NCI-H226 M3jOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fjV2lEPTB;NECzMlI{KG6P MmrYV2FPT0WU
COLO-668 M3fXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TGeGlEPTB;NECzMlU4KG6P NHPuPYFUSU6JRWK=
CPC-N M3\W[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y1S2lEPTB;NECzMlc4KG6P NFK0VYJUSU6JRWK=
NCI-H889 NXrPeWZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDzO|hEUUN3ME20OlEvQTJibl2= NYDpWodSW0GQR1XS
J-RT3-T3-5 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\4Oo1rUUN3ME21N|IvPTdibl2= NFvwUmhUSU6JRWK=
MSTO-211H M4e3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPSfFVKSzVyPUW3OE4zPiCwTR?= MoHlV2FPT0WU
SCC-15 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DyeWlEPTB;Nk[3MlQ4KG6P MYrTRW5ITVJ?
SUP-T1 NInPPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnITXp7UUN3ME22PFYvODRibl2= NHnJOWZUSU6JRWK=
DMS-153 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLZTWM2OD15NE[uPFMhdk1? MkTlV2FPT0WU
MS-1 NWrU[I03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTd3OT60NkBvVQ>? MmnHV2FPT0WU
TC-YIK MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXFW49{UUN3ME23PFEvODFibl2= Ml;sV2FPT0WU
RPMI-8866 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHzTWM2OD1zMEC2MlI5KM7:TR?= MUnTRW5ITVJ?
KY821 NFPwfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDTc2M4UUN3ME2xNFM3NjB2IN88US=> NGnZNplUSU6JRWK=
P31-FUJ NY\2ZWFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFzMUKuO|Uh|ryP M3XJNHNCVkeHUh?=
COLO-824 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjSTWM2OD1zMk[xMlc5KM7:TR?= MUfTRW5ITVJ?
U-698-M MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHDb4NKSzVyPUKyOlIvOTVizszN MnrmV2FPT0WU
TE-441-T NU\ZU4lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLUTGVKSzVyPUK1NlEvPyEQvF2= NYrjSHRRW0GQR1XS
IMR-5 M2[zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN2MEmuOlIh|ryP NFH5NIpUSU6JRWK=
NCI-H1838 NX;Kb5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjWS2tvUUN3ME20NVg3NjN{IN88US=> NXm0NnpvW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID